Novavax, Inc. fell 12.2% on Thursday, November 12, 2026, on 7,014,000 shares. The headline around the move:
Novavax, Inc. (NVAX:NASDAQ) closed at $8.53 on November 13, 2026, down 2.68% on the day. The stock trades 36.3% below its 52-week high of $13.39 and 37.5% above its 52-week low of $6.20. Over the past year, it gained 22.3%. Novavax, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since November 13, 2025, NVAX closed higher on 120 days (48%). Its best day was January 21, 2026 (+20.73%) and its worst was November 12, 2026 (-12.22%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 1 time.
Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Find more stocks like NVAX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.